Physician profile
Suyash Mohan
NPI 1821229691
$18,814.32
in general payments reported to CMS, 2019-2025
9 companies · $7,144 in 2025
The $7,144 reported for 2025 was more than what 85% of Neuroradiology providers received nationally (typical 2025 total: $278).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,386 · 2022: $61.93 · 2023: $417 · 2024: $7,806 · 2025: $7,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,578 · Travel and Lodging: $3,224 · Food and Beverage: $2,565.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,577.50 |
| Travel and Lodging | $3,223.72 |
| Food and Beverage | $2,565.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Servier Pharmaceuticals LLC | $7,587.05 | 2024 | |
| Novocure INC. | $4,186.02 | 2019-2025 | Optune, Optune Gio |
| Telix Pharmaceuticals | $3,396.63 | 2025 | Illuccix |
| Guerbet LLC | $3,352.17 | 2025 | Elucirem |
| Medtronic, INC. | $190.69 | 2023-2025 | Abre |
| Bayer Healthcare Pharmaceuticals INC. | $93.40 | 2019 | |
| Novocure Gmbh | $8.36 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suyash Mohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.